Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution
Jan 07, 2021 - Nasdaq
Mergers and Acquisitions
Radius Health, Inc. RDUS announced a definitive agreement to acquire the global development and commercialization rights of Benuvia Therapeutics Inc.’s synthetic cannabidiol oral solution (“RAD011”).
RAD011 is a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases.
The initial indication, for which the candidate will be evaluated, is Prader-Willi syndrome (“PWS”).
Radius intends to begin a phase II/III stud...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
